Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Michael L WangJacqueline C BarrientosRichard R FurmanMatthew MeiPaul M BarrMichael Y ChoiSven de VosAvyakta KallamKrish PatelThomas J KippsSimon RuleKate FlandersKatti A JessenHong RenPeter C RieblingPatricia GrahamLydia KingArchie W ThurstonMichael SunElizabeth M SchmidtBrian J LannuttiDavid M JohnsonLangdon L MillerStephen E SpurgeonPublished in: NEJM evidence (2021)
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers In a Phase 1 trial, patients with refractory lymphoid cancers, an antibody-drug complex directed against ROR1 had no unexpected toxicities. About half of the patients with mantle cell lymphoma and diffuse large B-cell lymphoma had clinically meaningful responses.